Anbenitamab is a new second-line option in G/GEJ adenocarcinoma

Nature Reviews Clinical Oncology 2026

View at publisher

Authors: Diana Romero

DOI: 10.1038/s41571-026-01124-3

Cited by: 0

References: 1

Fields of Study & Subjects

Gastric Cancer Management and Outcomes HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations

References 1